# BridgeBio Oncology Therapeutics, Inc.: Form SCHEDULE 13D/A, filed Jul 6, 2026

- Company: [BridgeBio Oncology Therapeutics, Inc.](/companies/bbot.md) (CIK 1869105)
- Form: SCHEDULE 13D/A
- Filed: 2026-07-06
- Accepted by EDGAR: Jul 6, 2026, 16:37 ET
- Period: not reported
- Accession: 0001213900-26-075546
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1869105/000121390026075546/xslSCHEDULE_13D_X02/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1869105/000121390026075546/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1869105/000121390026075546/xslSCHEDULE_13D_X02/primary_doc.xml

Filed Jul 6, 2026.
Source: SEC EDGAR, the filing index for accession 0001213900-26-075546. Last ingested by Listed: Nov 14, 2026, 20:40 ET. No prices; not investment advice.